Barrett's Esophagus, GERD
Conditions
Keywords
Barrett's esophagus, GERD
Brief summary
Patients with Barrett's Esophagus are known to have excessive distal esophageal acid exposure comparable to patients with erosive esophagitis. A significant proportion of patients with BE who are not symptomatic on treatment continue to have persistent acid reflux. High dose esomeprazole is able to control acid reflux in patients with BE. The effect of acid reflux on Barrett's esophagus stroma is currently unknown. It is our hypothesis that stromal fibroblast activation in Barrett's esophagus is influenced by acid reflux. The specific aim of this proposal will be: To assess the association between acid reflux and subepithelial fibroblasts in Barrett's esophagus.
Detailed description
We will conduct a prospective cohort study to assess the degree of stromal activation in patients with LSBE (without dysplasia) who have adequate and inadequate control of acid reflux in the distal esophagus. The study will be conducted in two phases. Phase 1 (Pilot): 20 patients with LSBE without dysplasia will undergo endoscopy with biopsies and a 24 hour pH study on treatment. Patients will then be divided into 2 groups: * Group A (GER): Those with ongoing acid reflux (characterized by either presence of esophagitis \[LA classification B,C or D1\] on endoscopy, and/or a positive pH study on treatment defined using standard criteria) * Group B (NGER): Those with controlled acid reflux (negative endoscopy and pH study on treatment). Stromal markers that will be assessed and compared between the 2 groups will include: presence of activated myofibroblasts (detected by immunohistochemistry for vimentin and smooth muscle actin).
Interventions
PROCEDUREEndoscopy and pH study
endoscopy and PH study done one time
Sponsors
AstraZeneca
Mayo Clinic
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Prior histological demonstration of Barrett's esophagus that is endoscopically visible; length of visible segment \>/= 1 cms * Absence of dysplasia on prior biopsies * Laboratory studies: * Prothrombin time (INR) \< 1.5 * Hemoglobin \> 8.0 gm/dL * Ability to provide informed consent
Exclusion criteria
* Eastern Cooperative Oncology Group performance status 3 or 4 * Inability to tolerate endoscopic procedures * Pregnancy: Females of child-bearing age will be screened with pregnancy test. Although none of the procedures in the study are contraindicated in pregnancy, sedation used in endoscopy can be contraindicated in early pregnancy * Prior esophageal surgery, or cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The specific aim of this proposal will be: To assess the association between acid reflux and subepithelial fibroblasts in Barrett's esophagus. | end of study |
Countries
United States
Outcome results
None listed